ADHD drugs lower risk of suicidal behaviour, car accidents, and crime
But a new study has identified other, longer term consequences. For people newly diagnosed with ADHD, the drugs are tied to a significantly lower risk of suicidal behaviour, alcohol or drug abuse, car accidents, and criminal activity.
The findings could be reassuring for the roughly 5 per cent of children and 2.5 per cent of adults who have ADHD, which can cause distraction, forgetfulness, high energy levels, restlessness, and other issues. Symptoms usually start before the age of 12.
The results 'are extremely important from a public health perspective and a clinical perspective,' Dr Samuele Cortese, one of the study's authors and a professor at the University of Southampton in the United Kingdom, said during a press briefing.
The study, published in the BMJ, included nearly 149,000 people ages 6 to 64 who were diagnosed with ADHD in Sweden from 2007 to 2020. Researchers compared people who started ADHD medication within three months of diagnosis with those who did not start treatment, and followed them for an average of two years.
Their goal was to mimic the design of a randomised controlled trial, where some people receive the intervention being tested – such as a new medicine – and others get a placebo or dummy treatment.
These trials are considered the gold standard in medical research, allowing scientists to home in on the effect of the new drug or intervention.
Other research has pointed to a link between untreated ADHD and job instability, anxiety, addiction, and other problems.
But the lack of randomised trials made it hard to prove that ADHD drugs actually lowered the risks. The latest study does not quite establish causation, but it comes closer.
ADHD medication was tied to a 17 per cent lower risk of suicide, attempted suicide, and suicidal thoughts, as well as a 15 per cent reduction in substance misuse, a 12 per cent reduction in transportation accidents, and a 13 per cent reduction in criminality.
The researchers said the lower risks could be because the drugs reduce impulsivity – which could curb criminality by reducing aggressive behaviour – and improve attention, which might minimise distractions and lower the risk of car accidents.
The study has some limitations, notably the fact that people could have collected their ADHD medications and then not taken them. The analysis also does not include incidents – for example, minor accidents – that were not serious enough to be captured in medical or legal records.
Even so, Cortese said doctors should consider the findings when they discuss possible ADHD treatment with their patients.
'When doctors discuss the potential use [of drugs] they focus on the type of medication and the side effects – which we don't need to underestimate, but oftentimes there is not information on what are the risks if you don't take' medication, he said.
'I think this is important to consider [that] if left untreated, there [could] be some unfortunate risks, and now we have evidence that medication can help reduce these risks'.
If you are contemplating suicide and need to talk, please reach out to Befrienders Worldwide, an international organisation with helplines in 32 countries. Visit befrienders.org to find the telephone number for your location.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
2 days ago
- Euronews
ADHD drugs lower risk of suicidal behaviour, car accidents, and crime
People with attention-deficit/hyperactivity disorder (ADHD) are often well aware of the side effects of medication, including difficulty sleeping, loss of appetite, and irritability. But a new study has identified other, longer term consequences. For people newly diagnosed with ADHD, the drugs are tied to a significantly lower risk of suicidal behaviour, alcohol or drug abuse, car accidents, and criminal activity. The findings could be reassuring for the roughly 5 per cent of children and 2.5 per cent of adults who have ADHD, which can cause distraction, forgetfulness, high energy levels, restlessness, and other issues. Symptoms usually start before the age of 12. The results 'are extremely important from a public health perspective and a clinical perspective,' Dr Samuele Cortese, one of the study's authors and a professor at the University of Southampton in the United Kingdom, said during a press briefing. The study, published in the BMJ, included nearly 149,000 people ages 6 to 64 who were diagnosed with ADHD in Sweden from 2007 to 2020. Researchers compared people who started ADHD medication within three months of diagnosis with those who did not start treatment, and followed them for an average of two years. Their goal was to mimic the design of a randomised controlled trial, where some people receive the intervention being tested – such as a new medicine – and others get a placebo or dummy treatment. These trials are considered the gold standard in medical research, allowing scientists to home in on the effect of the new drug or intervention. Other research has pointed to a link between untreated ADHD and job instability, anxiety, addiction, and other problems. But the lack of randomised trials made it hard to prove that ADHD drugs actually lowered the risks. The latest study does not quite establish causation, but it comes closer. ADHD medication was tied to a 17 per cent lower risk of suicide, attempted suicide, and suicidal thoughts, as well as a 15 per cent reduction in substance misuse, a 12 per cent reduction in transportation accidents, and a 13 per cent reduction in criminality. The researchers said the lower risks could be because the drugs reduce impulsivity – which could curb criminality by reducing aggressive behaviour – and improve attention, which might minimise distractions and lower the risk of car accidents. The study has some limitations, notably the fact that people could have collected their ADHD medications and then not taken them. The analysis also does not include incidents – for example, minor accidents – that were not serious enough to be captured in medical or legal records. Even so, Cortese said doctors should consider the findings when they discuss possible ADHD treatment with their patients. 'When doctors discuss the potential use [of drugs] they focus on the type of medication and the side effects – which we don't need to underestimate, but oftentimes there is not information on what are the risks if you don't take' medication, he said. 'I think this is important to consider [that] if left untreated, there [could] be some unfortunate risks, and now we have evidence that medication can help reduce these risks'. If you are contemplating suicide and need to talk, please reach out to Befrienders Worldwide, an international organisation with helplines in 32 countries. Visit to find the telephone number for your location.
Euronews
16-07-2025
- Euronews
What scientists got right - and wrong
At the dawn of the millennium, a group of esteemed scientists drew up a list of threats they deemed most likely to impact the world's rocky shores over the coming quarter of a century. Now, in 2025, the same academics and other experts have reviewed their forecasts and done another stocktake of Earth's coastlines. The new study, published in Marine Pollution Bulletin, reveals several points where they were spot on - and others where their predictions fell wide of the mark. 'Our shorelines are sentinels for the global ocean and, for many people, their window to what is happening in our seas,' says Professor Hawkins, Lankester Research Fellow at the Marine Biological Association (MBA), and an Emeritus Professor at the University of Southampton. 'Protecting their continued health is essential, but they are constantly facing multiple threats from land, sea and environmental change.' The first study, published in 2002, shows it is possible to forecast some challenges, he continues. 'However, there will always be things we can't foresee – and things that don't materialise as scientists might expect.' What did the scientists get right in their shoreline predictions? The scientists correctly predicted that oil spills would decrease in both frequency and volume - a trajectory that was already underway since the 1970s. Despite some major tanker-related spills, the biggest oil spill in the last two decades was offshore following the Deepwater Horizon catastrophe, when a drilling platform operated by BP in the Gulf of Mexico exploded. The use of more environmentally sensitive clean-up methods has also generally lessened the severity of any post-spill impacts. Professors Hawkins and co-author Professor Richard Thompson OBE FRS, Professor of Marine Biology at the University of Plymouth, were also right to predict that the global spread of non-native species would increase as global temperatures change. One example of an invasive species that has relocated as sea temperatures rise is the warm-water barnacle Austrominius modestus. Introduced to southern England in the 1940s, its range has now expanded into Europe - from Denmark to southern Portugal, and north into Scandinavia - where it tends to dominate in rocky intertidal areas. They were also correct to say that the growth of industrial agriculture, plus riverside and coastal urbanisation, would lead to increased sediment running into rivers, estuaries and seas. What went better than expected? Some forecasts were partially right. The 2002 study was insufficiently optimistic about reductions in the impacts of toxic chemicals, such as tributyltin (TBT), which were subsequently reined in by international legislation. 'Marine scientists have shown that a combination of global and local action can bring about positive change – the successful banning of TBT by the International Maritime Organization in 2003 being a notable example,' concludes Professor Thompson, who was recently named by TIME magazine among its 100 most influential people in the world for 2025. Another positive: concerns that offshore renewable energy installations might harm marine habitats have proved to be unfounded. Interestingly, the study notes, the growth of offshore wind installations has actually provided offshore habitat for some rocky shore species and stepping stones, thereby increasing the 'demographic connectivity' of populations. Climate change threats were underestimated While scientists were very aware of the influence of climate fluctuations, they didn't fully appreciate the varied impacts they would have on species and ecosystems. And they underestimated the importance of extreme weather events resulting from climate change. In the interim, other studies have warned how climate change is increasing the risk of extreme flooding and droughts, endangering coastal species which rely on natural salinity levels. Other threats the scientists missed 25 years ago include the impacts of coastal mining, ocean acidification and the staggering scale of plastic pollution. 'As international discussions continue around factors such as a Global Plastics Treaty and the most effective ways to reduce global warming, it is important that we recognise past environmental success and build on them,' says Professor Thompson. He and Professor Hawkins worked on the new study alongside Dr Kathryn O'Shaughnessy and other colleagues at the MBA and University of Plymouth and various other organisations across the UK, US, South Africa, Italy, Ireland, Chile, China and Monaco.
Sustainability Times
11-06-2025
- Sustainability Times
'Revolutionary Oral Treatment Shocks Experts': This New Sleep Apnea Remedy Slashes Respiratory Arrests by 56% Without a Maskatory Arrests by 56% Without a Mask
IN A NUTSHELL 🌟 AD109 is a new oral treatment that shows promise in reducing sleep apnea episodes without the use of CPAP machines. is a new oral treatment that shows promise in reducing sleep apnea episodes without the use of CPAP machines. 🔬 The medication combines atomoxetine and aroxybutynin to strengthen airway muscles, significantly lowering the frequency of respiratory interruptions. and to strengthen airway muscles, significantly lowering the frequency of respiratory interruptions. 📊 In clinical trials, patients experienced a 56% reduction in obstructive events and improved oxygen levels compared to a placebo. in obstructive events and improved oxygen levels compared to a placebo. 🚀 This innovation could mark a shift towards personalized medicine in sleep disorder treatment, offering a more convenient and effective solution for patients. Imagine a world where a simple pill can replace the cumbersome night masks for those suffering from sleep apnea. This vision is becoming a reality thanks to groundbreaking research and drug development in the field of obstructive sleep apnea (OSA). A recent clinical trial has demonstrated the efficacy of a novel oral treatment, marking a significant shift in how we approach this common yet debilitating condition. This article delves into the potential of this new treatment and its implications for millions of people affected by OSA. Understanding Sleep Apnea and Its Challenges Sleep apnea is a serious disorder characterized by repeated interruptions in breathing during sleep. These interruptions, or apneas, can lead to reduced oxygen levels, frequent awakenings, and increased risk for heart disease and stroke. Traditionally, the primary treatment for sleep apnea has been the CPAP (Continuous Positive Airway Pressure) machine. Although effective, many patients find it uncomfortable and difficult to adhere to. As a result, compliance rates are disappointingly low, leaving many without proper treatment. In recent years, the search for alternatives has intensified. The need for a more convenient and less invasive treatment option has never been greater. The emergence of a new oral medication offers hope for those who struggle with the burdens of CPAP therapy. By targeting the underlying causes of airway collapse, this medication could provide a much-needed solution to those seeking relief from the nightly struggles of sleep apnea. Longest-Range Drone Ship in History: UK's New 8,500-Mile Vessel Stuns Military Analysts With Unprecedented Unmanned Capabilities The Breakthrough Oral Treatment: AD109 The new treatment, known as AD109, combines two well-known drugs: atomoxetine and aroxybutynin. Atomoxetine is traditionally used to treat ADHD, while aroxybutynin is employed for bladder overactivity. Together, these medications strengthen the muscles of the upper airway, particularly the genioglossus muscle, which plays a crucial role in keeping the airway open during sleep. This innovative combination has demonstrated a remarkable ability to reduce apnea episodes and improve oxygen levels in patients. In a large-scale trial involving 646 patients, those treated with AD109 experienced a 56% reduction in obstructive events compared to the placebo group. Moreover, 22% of participants achieved near-complete control of their condition, with fewer than five apneas per hour. These results suggest that AD109 could revolutionize the management of sleep apnea, offering an effective and non-invasive alternative to traditional treatments. 'Japan Traps the Impossible': Scientists Develop Breakthrough Method to Extract Ammonia From Air and Water With Unmatched Precision Potential Benefits and Concerns The potential benefits of this treatment extend beyond symptom relief. By providing a more convenient and tolerable option, AD109 could improve patient adherence and overall health outcomes. The possibility of avoiding the discomfort and inconvenience of CPAP machines is a significant advantage for many patients. However, as with any new treatment, there are concerns that must be addressed. Some potential side effects, particularly those associated with atomoxetine, such as increased blood pressure and less restorative sleep, warrant careful monitoring. Long-term safety data is also necessary to ensure the continued well-being of patients. Despite these concerns, the excitement surrounding AD109 is palpable among researchers and clinicians, who are eager to see its impact on the future of sleep medicine. Scientists Stumble Onto Miracle Material That Instantly Harvests Drinking Water from Air With Zero Energy or Filters The Future of Sleep Medicine As we stand on the brink of a new era in sleep medicine, the implications of AD109 are profound. This breakthrough could signify a shift towards personalized medicine in the treatment of sleep disorders. By offering a targeted, effective solution, AD109 has the potential to transform sleep apnea management and improve the quality of life for countless individuals. The path to widespread use will involve further studies and regulatory approvals, with hopes that the FDA will approve the treatment by 2026. As researchers continue to explore and refine this approach, the prospect of a future where sleep apnea is no longer a nightly battle is within reach. This innovation could pave the way for further advancements in the field, inspiring new approaches to the treatment of other sleep-related disorders. As the medical community eagerly anticipates the potential approval and availability of AD109, one question remains: Will this new treatment truly replace the need for traditional therapies, or will it serve as a complement to existing options in the quest for better sleep health? Our author used artificial intelligence to enhance this article. Did you like it? 4.5/5 (30)
